Atea Pharmaceuticals (AVIR) Research & Development (2019 - 2026)

Atea Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $41.1 million for Q1 2026.

• In Q1 2026, Research & Development rose 39.04% year-over-year to $41.1 million; the TTM figure through Mar 2026 stood at $159.6 million (up 37.43% YoY), while the FY2025 annual figure was $148.0 million, up 2.72% from the prior year.
• Research & Development for Q1 2026 stood at $41.1 million, down from $47.8 million in the prior quarter.
• The five-year high for Research & Development was $57.6 million in Q1 2024, with the low at $4.9 million in Q3 2022.
• The 5-year median for Research & Development is $29.6 million (2025), against an average of $31.1 million.
• The sharpest annual moves came in 2022 and 2023: Research & Development sank 88.6% in 2022, then soared 474.54% in 2023.
• Atea Pharmaceuticals' Research & Development stood at $27.5 million in 2022, then advanced by 27.25% to $35.0 million in 2023, then fell by 26.75% to $25.7 million in 2024, then soared by 86.27% to $47.8 million in 2025, then slipped by 13.98% to $41.1 million in 2026.
• Business Quant data shows AVIR's Research & Development at $41.1 million in Q1 2026, $47.8 million in Q4 2025, and $38.3 million in Q3 2025.